Diana Blum
Neurology · Stanford, CANPI 1952599839
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,074 of the $13,083 with a category attached, or 69.4%. 19 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 41.3% of the total. Reporting peaked in 2019 at $5,978 and has fallen 92.8% since, to $427 in 2025.
Across 99 payments — averaging $132.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$5K
- Lundbeck LLC$4K
- Kyowa Kirin, Inc.$2K
- MDD US Operations, LLC$361
- AbbVie$257
- UCB, Inc.$241
- plus $642 from 13 others
What the payments were for
- Consulting fees$1,63913%
- Speaking & faculty fees$9,07469%
- Travel & lodging$2472%
- Food & beverage$2,12316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 25 | $5,400 |
| Lundbeck LLC | 7 | $4,467 |
| Kyowa Kirin, Inc. | 8 | $1,715 |
| MDD US Operations, LLC | 12 | $361 |
| AbbVie(2 entities) | 13 | $257 |
| UCB, Inc. | 6 | $241 |
| Adamas Pharmaceuticals, Inc. | 4 | $97 |
| Acadia Pharmaceuticals Inc | 4 | $82 |
| Amgen | 2 | $67 |
| Novartis | 3 | $60 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Vertical Pharmaceuticals, LLC | 2 | $49 |
| Acorda Therapeutics, Inc | 2 | $47 |
| Bausch Health US, LLC | 2 | $44 |
| Lilly USA, LLC | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 1 | $30 |
| Avion Pharmaceuticals | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,083 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 306 | $268,157 |
| NourianzIstradefylline | 85 | $226,530 |
| NuplazidPimavanserin Tartrate | 25 | $201,138 |
| InbrijaLevodopa | 38 | $145,108 |
| GocovriAmantadine Hcl | 20 | $125,742 |
| NeuproRotigotine | 87 | $110,204 |
| OngentysOpicapone | 70 | $60,450 |
| Droxidopa | 64 | $55,930 |
| XadagoSafinamide Mesylate | 12 | $36,577 |
| Rasagiline Mesylate | 68 | $15,477 |
| Rivastigmine | 26 | $8,431 |
| RivastigmineRivastigmine Tartrate | 25 | $2,476 |
| AmantadineAmantadine Hcl | 32 | $2,135 |
| NeurontinGabapentin | 14 | $2,020 |
| Memantine Hcl | 27 | $1,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $5,400 | $268,157306 claims |
| Kyowa Kirin, Inc.Nourianz | $1,715 | $226,53085 claims |
| Acadia Pharmaceuticals IncNuplazid | $82 | $201,13825 claims |
| Acorda Therapeutics, IncInbrija | $47 | $145,10838 claims |
| MDD US Operations, LLCGocovri | $361 | $125,74220 claims |
| UCB, Inc.Neupro | $241 | $110,20487 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.
Other neurology in Stanford
- Jeffrey DunnStanford$437K
- Neelam GoyalStanford$270K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.